| WHO | World Health Organization |
| PD | Parkinson’s disease |
| CNS | central nervous system |
| BBB | blood–brain barrier |
| AD | Alzheimer’s disease |
| Aβ | β-amyloid |
| GSK-3β | glycogen synthase kinase-3β |
| CDK5 | cyclin-dependent kinase 5 |
| TREM2 | Triggering Receptor Expressed on Myeloid cells 2 |
| NLRP3 | NOD-, LRR-, and pyrin domain-containing protein 3 |
| SNCA | synuclein alpha gene |
| PINK1 | PTEN-induced kinase 1 |
| GBA1 | Glucocerebrosidase 1 |
| ASOs | antisense oligonucleotides |
| GDNF | glial cell line-derived neurotrophic factor |
| ALS | amyotrophic lateral sclerosis |
| C9orf72 | chromosome 9 open reading frame 72 |
| SOD1 | superoxide dismutase 1 |
| TDP-43 | TAR DNA-binding protein 43 |
| HD | Huntington’s disease |
| HTT | huntingtin |
| AAV | adeno-associated virus |
| P-gp | P-glycoprotein |
| BCRP | breast cancer resistance protein |
| TfR | transferrin receptor |
| IR | insulin receptor |
| LRP1 | low-density lipoprotein receptor-related protein 1 |
| CSF | cerebrospinal fluid |
| clogP | calculated logP |
| PSA | polar surface area |
| MPO | multiparameter optimization |
| PET | positron emission tomography |
| LAT1 | L-type amino acid transporter 1 |
| LNPs | lipid nanoparticles |
| pKa | acid dissociation constant |
| GMP | Good Manufacturing Practices |
| PLGA-PEG | poly(lactic-co-glycolic acid)–polyethylene glycol |
| RVG29 | rabies virus glycoprotein 29 |
| MSNs | mesoporous silica nanoparticles |
| BDNF | brain-derived neurotrophic factor |
| iPSC | induced pluripotent stem cell |
| Fe3O4 | iron(II,III) oxide |
| MSC | mesenchymal stem cell |
| ROS | reactive oxygen species |
| RGDyK | arginylglycylaspartic acid-tyrosine-lysine |
| tMCAO | transient middle cerebral artery occlusion |
| MMP-9 | matrix metalloproteinase-9 |
| Rx | diagnostic and therapeutic |
| MRI | magnetic resonance imaging |
| FcRn | neonatal Fc receptor |
| AUC | area-under-the-curve |
| PrP | prion protein |
| siRNA | small interfering RNA |
| CED | Convection-Enhanced Delivery |
| VEE | Venezuelan equine encephalitis |
| saRNA | self-amplifying RNA |
| circRNA | circular RNA |
| SpCas9-HF1 | Streptococcus pyogenes Cas9-High Fidelity 1 |
| ABE8e | adenine base editor 8e |
| dCas9-KRAB-MeCP2 | deactivated Cas9 fused to a Krüppel-associated box and methyl-CpG-binding protein 2 |
| CAR | Chimeric Antigen Receptor |
| IL-10 | Interleukin-10 |
| TNF-α | tumor necrosis factor-alpha |
| IL-1β | Interleukin-1 beta |
| CD14 | Cluster of Differentiation 14 |
| NSC | neural stem cell |
| TK/GCV | thymidine kinase/ganciclovir |
| FUS | focused ultrasound |
| AADC | aromatic L-amino acid decarboxylase |
| UPDRS | Unified Parkinson’s Disease Rating Scale |
| AMF | alternating magnetic field |
| TRPV1 | transient receptor potential vanilloid 1 |
| PCI | photochemical internalization |
| FDA | U.S. Food and Drug Administration |
| ARIA | amyloid-related imaging abnormalities |
| PK–PD | pharmacokinetic–pharmacodynamic |
| CARPA | complement activation-related pseudo-allergy |
| pHEA | poly(2-hydroxyethyl aspartamide) |
| CCM | Chemistry, Controls, and Manufacturing |
| PDI | polydispersity index |
| vg | vector genomes |
| CEAs | cost-effectiveness analyses |
| ICER | incremental cost-effectiveness ratio |
| QALY | quality-adjusted life-year |
| EMA | European Medicines Agency |
| ATMP | Advanced Therapy Medicinal Product |
| AI | artificial intelligence |